Fever differential diagnosis approach flowchart


| Organ System | Critical | Emergent | Nonemergent |
|---|---|---|---|
| Respiratory | Bacterial pneumonia with respiratory failure | Pneumonia, peritonsillar abscess, epiglottitis | Otitis media, sinusitis, pharyngitis, bronchitis, influenza, TB, COVID-19 |
| Cardiovascular | - | Endocarditis, pericarditis | - |
| GI | Peritonitis | Appendicitis, cholecystitis, diverticulitis, intra-abdominal abscess | Colitis, enteritis |
| GU | - | Pyelonephritis, tubo-ovarian abscess, PID | Cystitis, epididymitis, prostatitis |
| Neurologic | Meningitis, cavernous sinus thrombosis | Encephalitis, brain abscess | - |
| Skin/Soft tissue | - | Cellulitis, infected decubitus ulcer, soft tissue abscess | - |
| Systemic | Sepsis/septic shock, meningococcemia | Influenza, COVID-19 | - |

| Category | Examples |
|---|---|
| Infectious | Occult abscess, TB (especially miliary), endocarditis (culture-negative), osteomyelitis, viral infections, zoonoses |
| Noninfectious inflammatory | Still's disease, RA, SLE, reactive arthritis, sarcoidosis, vasculitis, polymyalgia rheumatica, IBD, Familial Mediterranean Fever |
| Malignant | Lymphoma, leukemia, myelodysplastic syndrome; renal cell carcinoma, metastatic carcinoma, colon cancer, HCC, atrial myxoma |
| Other | Drug fever, factitious fever, undiagnosed in ~20% of cases |
| Feature | Consider |
|---|---|
| Travel history | Malaria, typhoid, viral hemorrhagic fevers, leishmaniasis |
| Zoonotic exposure | Brucellosis, Q fever, tularemia, bartonellosis (cat scratch) |
| Medications | Drug fever (often with eosinophilia, rash, ALP elevation) |
| IV drug use / prosthetic valve | Endocarditis |
| Indwelling catheter / surgery | Hospital-acquired: C. diff, wound infection, vascular catheter infection |
| Morning stiffness >1 hour | Rheumatoid arthritis, Still's disease |
| B symptoms (night sweats, weight loss) | Lymphoma, TB, endocarditis |
| Periodic/recyclical pattern | Malaria, Familial Mediterranean Fever, lymphoma (Pel-Ebstein) |
| Immunocompromised (HIV, chemo) | Opportunistic infections, broader organism coverage |
seizure management with proper pathway with doctors order case sheet
explain with a seizure case
Mr. Arjun R., 34-year-old male Brought to the Emergency Department by his wife at 10:05 AM Chief complaint (per wife): "He collapsed and started shaking while having breakfast. He hasn't woken up properly."
| Parameter | Value |
|---|---|
| BP | 148/92 mmHg |
| HR | 118 bpm |
| RR | 22 breaths/min |
| SpO2 | 89% on room air |
| Temperature | 38.7°C (101.7°F) |
| GCS | E1V1M2 = 4 (unresponsive, posturing) |
O2 via non-rebreather mask at 15 L/min - target SpO2 > 94%
╔══════════════════════════════════════════════════════════╗
║ ORDER 1 - FIRST-LINE BENZODIAZEPINE ║
║ ║
║ Lorazepam (Ativan) 0.1 mg/kg IV slow push ║
║ = 0.1 × 70 kg = 7 mg → give 4 mg IV (max per dose) ║
║ ║
║ Administer over 2 minutes ║
║ If seizure continues at 5 min → REPEAT x1 ║
║ Repeat dose: Lorazepam 4 mg IV ║
╚══════════════════════════════════════════════════════════╝
╔══════════════════════════════════════════════════════════╗
║ ORDER 2 - SECOND-LINE AED ║
║ ║
║ Levetiracetam (Keppra) 60 mg/kg IV ║
║ = 60 × 70 kg = 4200 mg IV ║
║ → Give 4000 mg IV in 100 mL NS over 15 minutes ║
║ ║
║ Rate: 267 mL/h via infusion pump ║
╚══════════════════════════════════════════════════════════╝
╔══════════════════════════════════════════════════════════╗
║ ORDER 3 - EMPIRIC MENINGITIS TREATMENT ║
║ (Fever + Headache 2 days + New seizure = HIGH SUSPICION ║
║ Do NOT wait for LP - treat immediately) ║
║ ║
║ Ceftriaxone 2 g IV q12h - STAT first dose ║
║ Vancomycin 25 mg/kg IV (= 1750 mg) q8-12h - STAT ║
║ Dexamethasone 0.15 mg/kg IV q6h x4 days ║
║ = 10.5 mg → give 10 mg IV (before or with 1st abx) ║
║ Acyclovir 10 mg/kg IV q8h (= 700 mg) - cover HSV ║
╚══════════════════════════════════════════════════════════╝
╔══════════════════════════════════════════════════════════╗
║ ORDER 4 - RSI (RAPID SEQUENCE INTUBATION) ║
║ ║
║ Pre-oxygenation: 100% O2 via BVM x3-5 min ║
║ ║
║ INDUCTION: ║
║ Ketamine 2 mg/kg IV = 140 mg IV push ║
║ (chosen: hemodynamically stable, may reduce seizures) ║
║ ║
║ PARALYTIC (SHORT-ACTING ONLY): ║
║ Succinylcholine 1.5 mg/kg IV = 105 mg IV push ║
║ *** SHORT-ACTING - duration 10 min *** ║
║ *** DO NOT use vecuronium/rocuronium long-acting *** ║
║ *** Paralysis will MASK ongoing seizure activity *** ║
║ ║
║ Post-intubation: Continuous EEG monitoring - STAT ║
║ ETT confirmed by waveform capnography + CXR ║
╚══════════════════════════════════════════════════════════╝
Why short-acting paralytic only? Long-acting paralytics stop the visible shaking but seizure activity continues silently in the brain (non-convulsive SE). EEG is the only way to detect ongoing seizure after paralysis.
╔══════════════════════════════════════════════════════════╗
║ ORDER 5 - REFRACTORY SE INFUSION ║
║ ║
║ Midazolam (Versed): ║
║ Loading dose: 0.2 mg/kg IV = 14 mg IV bolus ║
║ Then infusion: start at 0.05 mg/kg/h = 3.5 mg/h ║
║ Titrate by 0.05 mg/kg/h q15 min to seizure cessation ║
║ on EEG (max 2 mg/kg/h) ║
║ ║
║ Vasopressor on standby (hypotension anticipated): ║
║ Norepinephrine 0.05-0.3 mcg/kg/min if MAP < 65 mmHg ║
╚══════════════════════════════════════════════════════════╝
╔══════════════════════════════════════════════════════════╗
║ ORDER 6 - STAT LABS & IMAGING ║
║ ║
║ Blood: ║
║ - CBC with differential ║
║ - CMP: Na, K, Ca, Mg, Cl, CO2, BUN, Creatinine, glucose║
║ - LFTs + ammonia ║
║ - Serum lactate ║
║ - Blood cultures x2 (BEFORE antibiotics if possible, ║
║ but DO NOT delay antibiotics for cultures) ║
║ - HIV screen ║
║ - CRP, ESR, procalcitonin ║
║ - ABG (patient intubated) ║
║ ║
║ Imaging: ║
║ - CT brain non-contrast STAT ║
║ - CT brain with contrast (after non-contrast) ║
║ ║
║ Lumbar Puncture: ║
║ - AFTER CT brain clears herniation risk ║
║ - CSF: cell count, glucose, protein, Gram stain, ║
║ culture, HSV PCR, cryptococcal antigen, VDRL ║
╚══════════════════════════════════════════════════════════╝
| Test | Result | Interpretation |
|---|---|---|
| WBC | 18,400/μL (84% neutrophils, bands 12%) | Marked neutrophilia - bacterial infection |
| Na | 128 mEq/L | Hyponatremia (SIADH from meningitis) |
| Ca | 9.1 mg/dL | Normal |
| Mg | 1.9 mg/dL | Normal |
| Glucose | 79 mg/dL | Normal |
| CRP | 142 mg/L | Markedly elevated |
| Procalcitonin | 8.4 ng/mL | Strongly suggests bacterial infection |
| Blood cultures | Pending | - |
| CSF Parameter | Result | Normal |
|---|---|---|
| Opening pressure | 28 cm H2O | <20 |
| Appearance | Cloudy, turbid | Clear |
| WBC | 2,800/μL (95% PMNs) | <5 |
| Glucose | 22 mg/dL | >60% serum glucose |
| Protein | 385 mg/dL | 15-45 |
| Gram stain | Gram-positive diplococci | - |
╔══════════════════════════════════════════════════════════╗
║ FINAL STANDING ORDERS - NEURO ICU ║
║ ║
║ ANTIBIOTIC REGIMEN (continue): ║
║ Ceftriaxone 2 g IV q12h x14 days ║
║ Vancomycin - dose by pharmacy per levels ║
║ (target AUC/MIC 400-600) ║
║ Dexamethasone 0.15 mg/kg IV q6h x4 days (COMPLETE) ║
║ (reduces neurologic complications in pneumococcal) ║
║ Acyclovir - STOP once HSV PCR returns negative ║
║ ║
║ SEIZURE PROPHYLAXIS / MAINTENANCE: ║
║ Levetiracetam 500 mg IV q12h (maintenance dose) ║
║ Continue until seizure-free x48h then reassess ║
║ ║
║ MIDAZOLAM WEAN: ║
║ When EEG seizure-free x24h: decrease by 25% q4-6h ║
║ ║
║ HYPONATREMIA CORRECTION (Na 128): ║
║ Fluid restrict to 1000 mL/24h ║
║ 3% NaCl NOT needed (Na not < 120, no herniation) ║
║ Recheck Na q6h; correct no faster than 8-10 mEq/L/day ║
║ (rapid correction → osmotic demyelination syndrome) ║
║ ║
║ VENTILATOR SETTINGS (post-intubation): ║
║ Mode: Volume AC TV: 6 mL/kg IBW (= 420 mL) ║
║ PEEP: 5 cmH2O FiO2: 0.4 RR: 14 ║
║ Target: SpO2 >94%, PaCO2 35-40 mmHg ║
║ ║
║ MONITORING: ║
║ Continuous EEG x48h minimum ║
║ Neuro checks q1h (pupils, GCS as assessable) ║
║ ICP monitoring if clinical deterioration ║
║ HOB elevation 30° (reduce ICP) ║
╚══════════════════════════════════════════════════════════╝
T = 0 min → Patient arrives, actively seizing (~8 min into seizure)
→ O2, monitors, IV access, POC glucose
→ STATUS EPILEPTICUS declared
T = 2 min → Lorazepam 4 mg IV (1st dose)
T = 7 min → Lorazepam 4 mg IV (2nd dose)
→ No response → move to 2nd-line
T = 10 min → Levetiracetam 4000 mg IV started (over 15 min)
→ EMPIRIC MENINGITIS antibiotics started (ceftriaxone,
vancomycin, dexamethasone, acyclovir)
T = 22 min → Levetiracetam complete, seizure CONTINUES
→ REFRACTORY SE declared → intubation decision
T = 25 min → RSI: Ketamine 140 mg IV + Succinylcholine 105 mg IV
→ Intubated; continuous EEG attached
T = 28 min → Midazolam 14 mg IV bolus + infusion started 0.05 mg/kg/h
T = 35 min → EEG confirms SEIZURE CESSATION
→ Midazolam titrated to 0.1 mg/kg/h
T = 45 min → CT brain: meningeal enhancement, no herniation
T = 60 min → LP performed: CSF confirms bacterial meningitis
T = 90 min → Patient in Neuro-ICU, sedated but hemodynamically stable
→ Blood cultures growing Gram-positive diplococci
→ Antibiotics narrowed to high-dose ceftriaxone
Day 3 → EEG seizure-free; midazolam weaned and discontinued
→ Extubated; following commands
→ Na corrected to 136 mEq/L
Day 7 → Transfer to step-down; levetiracetam continued orally
→ Neurology follow-up arranged
→ Outpatient EEG in 4 weeks
| Point | Lesson |
|---|---|
| Fever + new seizure = meningitis until proven otherwise | Do not delay antibiotics waiting for LP or CT |
| Treat empirically before diagnosis is confirmed | Antibiotics + antivirals started at T=10 min, diagnosis confirmed at T=60 min |
| Benzodiazepines: max 2 doses then escalate | More doses = more respiratory depression, not more seizure control |
| Short-acting paralytic only during RSI | Long-acting masks ongoing electrical seizure activity |
| Hyponatremia contributed to seizure | Na 128 from SIADH (meningitis) lowers seizure threshold |
| Never delay treatment to do LP | LP is done AFTER CT clears herniation AND after antibiotics are started |
| Levetiracetam preferred 2nd-line here | No cardiac monitoring needed, rapid administration, safe with unknown cardiac history |
| Continuous EEG is mandatory post-intubation | NCSE (non-convulsive SE) is present in up to 24% of comatose patients |
Pregnancy safe Drugs with Frequency, case wise & tips tricks, clinical pearls
| Old FDA Category | Meaning |
|---|---|
| A | Controlled studies show no fetal risk - safest |
| B | Animal studies show no risk; no adequate human studies, OR animal risk not confirmed in humans |
| C | Animal studies show adverse effects; no adequate human data; give only if benefit outweighs risk |
| D | Evidence of human fetal risk; benefit may outweigh risk in serious conditions |
| X | Fetal risk clearly outweighs any benefit - CONTRAINDICATED |
Golden Rule: Untreated maternal disease is often MORE dangerous to the fetus than treating it with a relatively safe drug.
| Drug | FDA Category | Safe Trimester | Frequency | Use |
|---|---|---|---|---|
| Penicillin G/Amoxicillin | B | All trimesters | Amox: 500 mg TID x7d | UTI, strep throat, dental infections, syphilis |
| Amoxicillin-Clavulanate | B | All (caution T1) | 875/125 mg BID x7d | Skin infections, sinusitis, UTI - avoid in 1st trimester if possible |
| Cephalexin (1st gen) | B | All trimesters | 500 mg QID x7d | UTI, cellulitis, skin infections |
| Ceftriaxone | B | All trimesters | 1-2 g IV/IM once daily | Severe infections, gonorrhea, meningitis |
| Azithromycin | B | All trimesters | 500 mg x1, then 250 mg OD x4d | Atypical pneumonia, chlamydia |
| Erythromycin | B | All trimesters | 500 mg QID x7d | Alternative for penicillin allergy |
| Clindamycin | B | All trimesters | 300 mg TID x7d | BV, anaerobic infections, skin infections |
| Nitrofurantoin | B | T1, T2 only | 100 mg ER BID x5d | Uncomplicated UTI - AVOID at term (>36 wk) |
| Metronidazole | B | T2, T3 (caution T1) | 500 mg BID x7d | BV, trichomoniasis, anaerobic infections |
| Drug | FDA Category | Concern | Alternative |
|---|---|---|---|
| Trimethoprim-Sulfamethoxazole (TMP-SMX) | C/D | T1: folate antagonist (NTD risk); T3: neonatal jaundice, kernicterus | Use only if no alternative; avoid T1 and T3 |
| Ciprofloxacin/Fluoroquinolones | C | Cartilage damage in animal studies; avoid if possible | Use only for serious infections with no safer option |
| Gentamicin/Aminoglycosides | D | Fetal ototoxicity, nephrotoxicity | Short course acceptable for life-threatening sepsis |
| Drug | Risk |
|---|---|
| Tetracyclines (doxy, minocycline) | Dental discoloration, inhibits fetal bone growth |
| Chloramphenicol (T3) | Gray baby syndrome |
| Linezolid | Insufficient safety data |
Patient: Priya, 26-year-old, 18 weeks pregnant. Dysuria, frequency, urgency x2 days. Urine dipstick: nitrites +, leukocyte esterase +, no fever.
Cephalexin (Keflex) 500 mg PO QID x 7 days
(cephalosporins - Category B, safe all trimesters)
OR
Nitrofurantoin (Macrobid) 100 mg ER PO BID x 5 days
(Category B - safe T1 and T2; AVOID if > 36 weeks)
| Drug | FDA Category | Dose | Mechanism | Notes |
|---|---|---|---|---|
| Methyldopa (Aldomet) | B | 250 mg PO q6-8h; max 3 g/day | Central α2 agonist | Oldest, most studied; drug of choice historically; can cause depression/fatigue |
| Labetalol | C | 100-400 mg PO BID; IV: 20 mg bolus | α+β blocker | First-line for chronic HTN in pregnancy; also used IV for acute severe HTN |
| Nifedipine (extended-release) | C | 30-90 mg PO OD | CCB | Add-on to labetalol/methyldopa; also used for preterm labor (tocolysis) |
| Hydralazine | C | 5-10 mg IV/IM q20-40 min (acute); 10-50 mg PO QID (chronic) | Direct vasodilator | Used IV in acute hypertensive emergency; can cause reflex tachycardia |
| Nifedipine (immediate-release, oral) | C | 10-30 mg PO (acute) | CCB | For acute severe HTN in ED - not FDA-approved for this indication but used |
| Drug | Risk |
|---|---|
| ACE inhibitors (lisinopril, enalapril, ramipril) | Fetal renal tubular dysplasia, oligohydramnios, IUGR, neonatal renal failure, skull defects - teratogenic in T2/T3 |
| ARBs (losartan, valsartan, olmesartan) | Same as ACEi - contraindicated |
| Atenolol | IUGR, bradycardia in neonate |
| Sodium nitroprusside | Cyanide toxicity to fetus |
Patient: Sunita, 32-year-old, 34 weeks pregnant. BP 178/114 mmHg on 2 readings 15 min apart. Severe headache, epigastric pain. Urine protein +++. Platelet count 88,000. LFTs elevated 2x normal.
1. Labetalol 20 mg IV push over 2 min
If BP still ≥160/110 after 10 min → Labetalol 40 mg IV
If still not controlled → Hydralazine 5-10 mg IV q20 min
OR
Nifedipine 10-20 mg PO, may repeat in 30 min
TARGET: BP 140-150/90-100 mmHg
2. MAGNESIUM SULFATE - seizure prophylaxis:
MgSO4 4-6 g IV over 20 min (loading dose)
Then 1-2 g/h IV continuous infusion
Monitor: respiratory rate, urine output, reflexes, Mg levels
3. Delivery planning: definitive treatment for HELLP is delivery
Dexamethasone 12 mg IM q12h x2 doses (fetal lung maturity if <34 wk)
| Drug | FDA Category | Safe Trimester | Notes |
|---|---|---|---|
| Paracetamol/Acetaminophen | B | All trimesters (short-term) | Drug of choice for pain and fever in all trimesters; recent data on prolonged use showing possible ADHD link but short-term use acceptable |
| Opioids (codeine, morphine, oxycodone) | C (T1/T2) / D (T3) | Short-term use only | Risk of NAS (neonatal abstinence syndrome) with prolonged use; avoid at term |
| Drug | Trimester | Risk |
|---|---|---|
| NSAIDs (ibuprofen, diclofenac, naproxen) | T3 - AVOID | Premature closure of ductus arteriosus, oligohydramnios, fetal renal impairment. T1 use: possible increased miscarriage risk |
| Aspirin (full dose >150 mg/day) | T3 | Antiplatelet effects, neonatal bleeding. LOW-DOSE aspirin 75-150 mg OD is actually recommended to prevent preeclampsia |
Patient: Asha, 28-year-old, 24 weeks pregnant. Severe tension headache and low back pain.
1. Paracetamol 500-1000 mg PO q6-8h PRN (max 4 g/day) - FIRST LINE
2. Warm compress for back pain (not hot - no heating pads directly on abdomen)
3. Non-pharmacologic: physiotherapy, support belt for back pain
| Drug | FDA Category | Dose | Notes |
|---|---|---|---|
| Pyridoxine (Vitamin B6) | A | 10-25 mg TID | First-line; safest; take 30 min before meals |
| Doxylamine + Pyridoxine (Diclegis/Bonjesta) | A | 2 tabs at bedtime (delayed-release) | FDA-approved combination; gold standard for NVP |
| Ginger (non-pharmacologic) | - | 250 mg QID or ginger tea | Shown effective in multiple trials; safe |
| Metoclopramide | B | 10 mg IV/PO TID | Safe; risk of extrapyramidal effects with prolonged use |
| Promethazine | C | 12.5-25 mg PO/IV/IM q4-6h | Effective but sedating; AAP cautions in nursing |
| Prochlorperazine | C | 5-10 mg PO/IV TID-QID | For refractory NVP; sedating |
| Ondansetron (Zofran) | B | 4-8 mg IV/PO q6-8h | Use for severe/refractory cases; some studies suggest possible cardiac septum defect and cleft palate risk - data inconsistent. Avoid in T1 if possible, use if severely symptomatic |
Patient: Riya, 10 weeks pregnant, 5 kg weight loss, unable to tolerate any oral intake, ketonuria ++, vomiting 12x/day.
ADMIT - IV Access
1. IV Fluids: Normal saline 0.9% + 40 mEq KCl/L @ 125 mL/h
(correct dehydration + electrolytes)
2. Thiamine 100 mg IV BEFORE glucose infusion
(prevent Wernicke's encephalopathy)
3. Ondansetron 4 mg IV q8h
+ Metoclopramide 10 mg IV TID
4. Pyridoxine 25 mg IV/PO TID (continue throughout)
5. Once tolerating oral fluids:
Step down to oral antiemetics
Doxylamine/Pyridoxine 2 tabs HS
6. Monitor: electrolytes, LFTs (exclude acute fatty liver), TFTs
(HCG stimulates TSH-R → gestational thyrotoxicosis in 60% of HG)
| Drug | Malformation Risk | Specific Risk | Verdict |
|---|---|---|---|
| Lamotrigine | Lowest among AEDs (~1%) | Levels fall precipitously in pregnancy - monitor and adjust | Preferred AED in pregnancy |
| Levetiracetam | Low (not associated with increased malformations) | Levels may fall; adjust by monitoring | Preferred; rapidly gaining favor |
| Carbamazepine | 4-5% major malformations | Cleft palate, NTD, fetal anticonvulsant syndrome | Use only if only effective agent |
| Phenytoin | 4-5% | Fetal hydantoin syndrome: midface hypoplasia, finger hypoplasia, NTD | Avoid if possible |
| Phenobarbital | 6-7% | NTDs, cardiac defects, cleft palate; neonatal bleeding | Avoid if possible |
| Valproate | 20% serious adverse outcomes | NTD (spina bifida 1-2%), cardiac defects, autism, IQ reduction (9 points), fetal valproate syndrome | AVOID - absolute contraindication in women of childbearing age without contraception |
| Topiramate | ~4% | Cleft palate, IUGR | Avoid |
| Drug | Safety | Dose | Notes |
|---|---|---|---|
| Levothyroxine (T4) | Safe - Category A | Adjust to maintain TSH 0.1-2.5 mIU/L | Hypothyroidism MUST be treated - untreated leads to fetal neurological damage; requirements increase ~25-30% in pregnancy |
| Propylthiouracil (PTU) | Preferred in T1 | Lowest effective dose; TID dosing | Drug of choice for hyperthyroidism in T1 (hepatotoxicity risk but crosses placenta less than methimazole) |
| Methimazole (MMI/Carbimazole) | Use in T2/T3 | Lowest effective dose; OD or BID dosing | Associated with aplasia cutis and "methimazole embryopathy" in T1 - switch to PTU in T1, back to MMI in T2 |
Patient: Nidhi, 8 weeks pregnant. Palpitations, tremor, weight loss despite increased appetite. TSH < 0.01, FT4 elevated 3x normal. Anti-TPO antibodies positive. Thyroid scan shows diffuse uptake.
Propylthiouracil (PTU) 100 mg PO TID
(preferred in T1 - less teratogenic during organogenesis)
Target: FT4 in upper normal range;
do NOT normalize TFTs (risk of fetal hypothyroidism)
At 13 weeks: Switch to Methimazole 10-20 mg PO OD
Monitor: TFTs q4 weeks; adjust dose to maintain FT4 high-normal
Check fetal heart rate at each visit - fetal tachycardia suggests
fetal hyperthyroidism from maternal antibody transfer
NEVER use: Radioiodine (I-131) - destroys fetal thyroid
NEVER use: Atenolol for prolonged rate control (IUGR risk)
Propranolol: short-term use acceptable for symptomatic tachycardia
| Drug | Safety | Route | Notes |
|---|---|---|---|
| Heparin (unfractionated) | Safe - does NOT cross placenta | IV/SC | Safe in all trimesters; drug of choice for anticoagulation in pregnancy |
| Low-Molecular-Weight Heparin (LMWH) - Enoxaparin, Dalteparin | Safe - does NOT cross placenta | SC | Preferred over UFH (once or twice daily SC; more predictable); dose-adjust by anti-Xa levels |
| Warfarin | Category D/X | Oral | Teratogenic in T1 (warfarin embryopathy: nasal hypoplasia, stippled epiphyses); CNS defects in T2/T3; fetal bleeding |
| Direct oral anticoagulants (DOACs) - apixaban, rivaroxaban | CONTRAINDICATED | Oral | Cross placenta; teratogenic; insufficient safety data |
| Drug | FDA Category | Verdict |
|---|---|---|
| SSRIs - Sertraline, Fluoxetine | C | Generally preferred if antidepressant needed; sertraline has best safety profile in pregnancy; avoid paroxetine (cardiac septal defects) |
| Sertraline | C | Most commonly used SSRI in pregnancy; minimal placental transfer |
| Paroxetine | D | Increased cardiac defects (VSD); AVOID |
| SNRIs - Venlafaxine | C | Limited data; use if SSRI inadequate |
| TCAs | C/D | Avoid if possible; nortriptyline safer than amitriptyline |
| Lithium | D | Ebstein's anomaly (small but real risk); requires detailed fetal cardiac echo at 20 weeks if used |
| Valproate | D | AVOID in pregnancy for psychiatric indications |
| Benzodiazepines | D | Neonatal withdrawal syndrome; cleft palate risk debated; avoid in T1; use minimum effective dose if needed in acute anxiety |
| Antipsychotics (olanzapine, quetiapine) | C | Risk of neonatal extrapyramidal symptoms; use lowest effective dose; all carry metabolic risks in mother |
| Drug | Safety | Notes |
|---|---|---|
| Salbutamol/Albuterol (SABA inhaler) | B - Safe | Drug of choice for acute bronchospasm; use unrestricted |
| Budesonide (ICS) | B - Preferred | Preferred inhaled corticosteroid; most safety data |
| Fluticasone (ICS) | C - Acceptable | Less data than budesonide but widely used |
| Salmeterol (LABA) | C - Use with ICS only | Add-on to ICS for poorly controlled asthma |
| Montelukast (LTRA) | B - Safe | Can continue if well controlled on it pre-pregnancy |
| Oral prednisolone | C - Use for exacerbations | Risk of cleft palate with T1 use (small); risk of uncontrolled asthma far greater - use when needed |
| Theophylline | C - Use with caution | Narrow therapeutic index; neonatal toxicity; use only if other agents fail |
| Drug | Safety | Notes |
|---|---|---|
| Clotrimazole (topical) | B - Safe | First-line for VVC (vaginal candidiasis) in pregnancy |
| Miconazole (topical) | C - Acceptable | Topical use safe |
| Nystatin (topical/oral) | B - Safe | Oral nystatin for thrush - minimal systemic absorption |
| Fluconazole oral | D - AVOID | Single dose (150 mg) controversial; repeated doses linked to fetal cardiac defects and craniosynostosis. Avoid especially in T1 |
| Amphotericin B | B - Acceptable | For serious systemic fungal infections only |
| Condition | First Choice | Avoid |
|---|---|---|
| UTI | Cephalexin, Nitrofurantoin (avoid T3) | TMP-SMX (T1, T3), fluoroquinolones |
| Hypertension | Labetalol, Methyldopa, Nifedipine ER | ACEi, ARBs, atenolol |
| HTN emergency | Labetalol IV, Hydralazine IV, Nifedipine oral | Sodium nitroprusside |
| Eclampsia seizure | Magnesium sulfate IV | Phenytoin (less effective) |
| Nausea/vomiting | Pyridoxine + Doxylamine, Metoclopramide | None first-line |
| Pain/fever | Paracetamol | NSAIDs (T3), full-dose aspirin |
| Diabetes | Insulin (preferred), Metformin (T2D/GDM) | Sulfonylureas (stop 2 wk before delivery) |
| Hypothyroidism | Levothyroxine | - |
| Hyperthyroidism | PTU (T1), Methimazole (T2/T3) | Radioiodine (I-131) |
| Epilepsy | Lamotrigine, Levetiracetam | Valproate, Topiramate |
| DVT/PE | LMWH (Enoxaparin) | Warfarin (T1), DOACs |
| Asthma (acute) | Salbutamol inhaler, Budesonide ICS | - |
| Depression | Sertraline | Paroxetine, Valproate |
| VVC (candida) | Clotrimazole topical | Oral fluconazole (T1) |
| Preeclampsia prophylaxis | Low-dose Aspirin 75-150 mg OD from 12 wk | - |
ortho cases with proper drug dose and frequency with clinical case examples opd,ward & icu